Zentalis Pharmaceuticals Inc (ZNTL)

$1.64 +0.09 (5.81%)
Market Cap 111.81M
Revenue (ttm) 67.43M
Net Income (ttm) -165.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -245.94%
Debt to Equity Ratio 0.00
Volume 573,100
Avg Vol 718,886
Day's Range N/A - N/A
Shares Out 72.14M
Stochastic %K 77%
Beta 1.77
Analysts Sell
Price Target $5.74

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 433 3791
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
Sillyspuh
Sillyspuh Oct. 9 at 3:16 PM
$ZNTL Keep going
0 · Reply
lucabrix
lucabrix Oct. 9 at 3:05 PM
$ZNTL getting some stream, turning point at 1.85
0 · Reply
kiwitc2000
kiwitc2000 Oct. 9 at 1:38 PM
$ZNTL Buying some cash here.
0 · Reply
Biotechnicity
Biotechnicity Oct. 8 at 5:26 PM
$ZNTL needs volume
0 · Reply
VM0007
VM0007 Oct. 6 at 2:33 PM
$ZNTL Last week, Genmab bought out Merus for $8 billion or, net of cash, 7x 2029 expected sales of their semtamab in Phase 3. Zentalis' azenosertib has an addressable market of $1 billion (based on Abbvie Elahere's sales) but it is trading at 35cents/$1.00 of cash.
1 · Reply
rao4
rao4 Oct. 3 at 8:29 PM
$ZNTL buyout could be one option too. Just two months after the chief legal officer was brought in by Julie Eastland at harpoon, they sold the company to merck..hope same happens in our case too..it's a very unusual company where the entire board and management is filled with ex trillium and harpoon guys..one was sold to Pfizer and other to merck
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Oct. 3 at 5:04 PM
$ZNTL took a 10k starter here today.
0 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 1:07 PM
$ZNTL Cam Gallagher should be investigated.
1 · Reply
Biotechnicity
Biotechnicity Oct. 3 at 3:42 AM
$ZNTL I do think this purchase establishes a floor at $1.50 (false though it may be) and is intended to drive the stock price higher. For what reason it doesn’t matter as I’m out at 3 — a double for me.
1 · Reply
LabPsycho
LabPsycho Oct. 2 at 8:42 PM
$ZNTL @Snackdaddy I do not think acquiring shares when the price of the Derivative is $0, counts as 'insider buying" https://ir.zentalis.com/node/10826/html
2 · Reply
Latest News on ZNTL
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 5:20 PM EDT - 7 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:27 PM EDT - 4 weeks ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:15 PM EDT - 5 weeks ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26, 2025, 4:05 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 5:00 PM EDT - 3 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 4:05 PM EDT - 5 months ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 4:05 PM EDT - 7 months ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:40 PM EDT - 7 months ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 15, 2025, 11:25 AM EDT - 7 months ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 29, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 28, 2025, 4:05 PM EST - 9 months ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 10 months ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 11 months ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 1 year ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 1 year ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Sillyspuh
Sillyspuh Oct. 9 at 3:16 PM
$ZNTL Keep going
0 · Reply
lucabrix
lucabrix Oct. 9 at 3:05 PM
$ZNTL getting some stream, turning point at 1.85
0 · Reply
kiwitc2000
kiwitc2000 Oct. 9 at 1:38 PM
$ZNTL Buying some cash here.
0 · Reply
Biotechnicity
Biotechnicity Oct. 8 at 5:26 PM
$ZNTL needs volume
0 · Reply
VM0007
VM0007 Oct. 6 at 2:33 PM
$ZNTL Last week, Genmab bought out Merus for $8 billion or, net of cash, 7x 2029 expected sales of their semtamab in Phase 3. Zentalis' azenosertib has an addressable market of $1 billion (based on Abbvie Elahere's sales) but it is trading at 35cents/$1.00 of cash.
1 · Reply
rao4
rao4 Oct. 3 at 8:29 PM
$ZNTL buyout could be one option too. Just two months after the chief legal officer was brought in by Julie Eastland at harpoon, they sold the company to merck..hope same happens in our case too..it's a very unusual company where the entire board and management is filled with ex trillium and harpoon guys..one was sold to Pfizer and other to merck
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Oct. 3 at 5:04 PM
$ZNTL took a 10k starter here today.
0 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 1:07 PM
$ZNTL Cam Gallagher should be investigated.
1 · Reply
Biotechnicity
Biotechnicity Oct. 3 at 3:42 AM
$ZNTL I do think this purchase establishes a floor at $1.50 (false though it may be) and is intended to drive the stock price higher. For what reason it doesn’t matter as I’m out at 3 — a double for me.
1 · Reply
LabPsycho
LabPsycho Oct. 2 at 8:42 PM
$ZNTL @Snackdaddy I do not think acquiring shares when the price of the Derivative is $0, counts as 'insider buying" https://ir.zentalis.com/node/10826/html
2 · Reply
Sillyspuh
Sillyspuh Oct. 2 at 6:05 PM
$ZNTL I'm calling it--this one is headed over $2 in the next week or two
1 · Reply
Snackdaddy
Snackdaddy Oct. 2 at 12:42 PM
$ZNTL insider just bought $260K worth of stock at $1.54. The insiders continue to bet on this
0 · Reply
Harlyboy
Harlyboy Oct. 2 at 1:08 AM
$ZNTL looks like institutions just dumped a bunch of shares. But why would all these prominent people join the company if it were gonna flop???? i wanna believe in it so bad
1 · Reply
rao4
rao4 Sep. 29 at 7:25 PM
$ZNTL hopeless stock at the moment.. trading at 1/3 and still finds more sellers..and todays volume is higher than normal
0 · Reply
Sillyspuh
Sillyspuh Sep. 26 at 7:22 PM
$ZNTL This same pump happened a few days ago before falling before the close. Will it happen again or stay?
1 · Reply
rao4
rao4 Sep. 25 at 7:38 PM
$ZNTL the valuation looks very attractive compared to all the biotechs. 1/3 of cash in hand. Still holding lot of shares.my only fear is why are they not releasing updated results from the ongoing study. Last datacut was in Jan 2025. If they release updated results the stock will definitely recover
0 · Reply
JCH007
JCH007 Sep. 24 at 8:19 PM
$ZNTL Anyone know what the news was that caused the pop? Heard it mentioned on Benzinga's High-Beta Squawk, but missed the details.
0 · Reply
BannedByStocktwits
BannedByStocktwits Sep. 24 at 5:08 PM
$ZNTL is this a buy ?
0 · Reply
Snackdaddy
Snackdaddy Sep. 19 at 8:01 PM
$ZNTL good volume but went nowhere
0 · Reply
Alien1980
Alien1980 Sep. 19 at 7:25 PM
$ABP $HUMA $TELO $UAVS $ZNTL all swing setups. Up 15% or more on each.
0 · Reply
lucabrix
lucabrix Sep. 19 at 3:42 PM
$ZNTL come to me 10$!
0 · Reply
Biotechnicity
Biotechnicity Sep. 19 at 3:35 PM
$ZNTL come to me $3.00
0 · Reply